The irrationality of a non-specific immunomodulation therapy used in cardiovascular diseases deserves a critical comment

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 38-39

  Bocci, Velio ^a   Zanardi, Iacopo ^a   Travagli, Valter ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEME OXYGENASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; OZONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CARCINOGENESIS; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DOWN REGULATION; HEART FAILURE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIMB ISCHEMIA; LIMB SALVAGE; MAJOR CLINICAL STUDY; NOTE; OXIDATIVE STRESS; OZONE THERAPY; PRIORITY JOURNAL; ULTRAVIOLET IRRADIATION; UPREGULATION; WOUND HEALING; CHEMICALLY INDUCED; ISCHEMIA; LIMB; NEOPLASM; VASCULARIZATION;

EXTREMITIES; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSION; ISCHEMIA; NEOPLASMS; OZONE; WOUND HEALING;

EID: 77954309658     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.04.014     Document Type: Note

References (16)

1. Bulmer J., Bolton A.E., Pockley A.G. Effect of combined heat, ozonation and ultraviolet irradiation (VasoCare) on heat shock protein expression by peripheral blood leukocyte populations. J Biol Regul Homeost Agents 1997, 11:104-110.
2. Bocci V., Borrelli E., Travagli V., Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev 2009, 29:646-682.
3. Travagli V., Zanardi I., Bernini P., et al. Effects of ozone blood treatment on the metabolite profile of human blood. Int J Toxicol 2010, 29:165-174.
4. Garber G.E., Cameron D.W., Hawley-Foss N., Greenway D., Shannon M.E. The use of ozone-treated blood in the therapy of HIV infection and immune disease: a pilot study of safety and efficacy. AIDS 1991, 5:981-984.
5. SIMPADICO-Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes. Available at: [accessed April 9, 2010]. http://clinicaltrials.gov/ct2/show/NCT00111826.
6. Olin J.W. Peripheral arterial disease: efficacy of immune modulation. Presented at: 55th Annual Scientific Sessions, Smaller Late-Breaking Clinical Trials I 2006, Available at: http://incirculation.net/3430_68539.aspx?parentaid=67695 [accessed April 9, 2010].
7. Torre-Amione G., Sestier F., Radovancevic B., Young J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004, 44:1181-1186.
8. Torre-Amione G., Anker S.D., Bourge R.C., et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008, 371:228-236.
9. Bolton A.E. Biologic effects and basic science of a novel immune-modulation therapy. Am J Cardiol 2005, 95:24C-29C.
10. Sliwa K., Ansari A.A. Immunosuppression as therapy for congestive heart failure. Lancet 2008, 371:184-186.
11. Sporter R.J., Kim J.H., Frishman W.H. Device-based nonspecific immunomodulation therapy (Celacade), and its potential role in the treatment of chronic heart failure. Cardiol Rev 2008, 16:280-287. [Erratum in: Cardiol Rev 2009;17:43].
12. Bocci V. Non-specific immunomodulation in chronic heart failure. Lancet 2008, 371:2083.
13. Bocci V. The failure of the ACCLAIM trial is due to an irrational technology. Int J Cardiol 2010, 139:304-305.
14. Bocci V., Aldinucci C., Mosci F., et al. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm 2007, 26785. doi:10.1155/2007/26785.
15. Di Paolo N., Bocci V., Salvo D.P., et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int J Artif Organs 2005, 28:1039-1050.
16. Marfella R., Luongo C., Coppola A., et al. Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option critical limb ischemia patients. Atherosclerosis 2010, 208:473-479.